Celldex Therapeutics, Inc. (CLDX), Wednesday announced results from phase 2 study of barzolvolimab for treatment of chronic spontaneous urticaria, an immune-related condition.
At the end of 52 weeks, the biotechnology company found that 71 percent of the participants treated with barzolvolimab achieved complete response.
Moreover, improvements in weekly urticaria activity score or UAS7 were reported from week 1.
Currently, Celldex's stock is dropping 24.11 percent, to $31.08 over the previous close of $40.96 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.